OTIS disclosure: EVP & CPO holds 5,688 shares plus RSUs and SARs totaling 21,055
Rhea-AI Filing Summary
Kimberly Shannon Gosk, EVP & CPO of Otis Worldwide (OTIS), reported direct ownership of 5,688 common shares and disclosed equity awards representing 21,055 underlying shares: 2,245 restricted stock units (RSUs) that convert one-for-one into common stock and 18,810 stock appreciation rights (SARs) with specified exercise prices. The RSUs vest in scheduled annual installments and several SAR tranches are fully or partially exercisable, as detailed in the filing.
Positive
- Direct equity ownership plus awards: The reporting officer holds 5,688 common shares and equity awards totaling 21,055 underlying shares, aligning pay with shareholder outcomes.
- Transparent disclosure: The filing specifies RSU conversion, dividend equivalent treatment, SAR tranche sizes, and exercise prices, improving investor visibility.
Negative
- Potential dilution: If RSUs vest and SARs are exercised, they will increase the number of outstanding shares and could be dilutive to existing shareholders.
Insights
TL;DR: Routine officer disclosure that increases transparency; holdings align executive pay with shareholder outcomes.
The Form 3 documents an executive-level beneficial ownership position and the structure of equity incentives. The filing provides clear counts for direct shares, RSUs and SARs and notes vesting/exercise schedules, which aids governance oversight. Impact on existing shareholders appears informational rather than material given no indication of extraordinary concentration or unusual compensation structures in the filing.
TL;DR: Mix of RSUs and SARs with staggered vesting/exercise reflects standard long-term incentive design.
The awards combine one-for-one RSUs that include dividend equivalents and multiple SAR tranches with explicit exercise prices and staggered exercisability. Several SAR grants are fully exercisable while others vest in installments, demonstrating a multi-year retention and performance alignment approach. The filing lists exercise prices per tranche, allowing assessment of potential intrinsic value when compared to market prices (not provided here).
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Stock Appreciation Rights | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (9)
- F1. Restricted Stock Units (RSUs) convert into common stock on a one-for-one basis and include the right to receive dividend equivalents that are credited as additional RSUs.
- F2. These RSUs are scheduled to vest in three substantially equal annual installments beginning on the first anniversary of the date of grant. The date of grant was February 4, 2025.
- F3. These RSUs are scheduled to vest in two substantially equal annual installments on the second and third anniversaries of the date of grant. The date of grant was February 6, 2024.
- F4. These RSUs are scheduled to vest on the third anniversary of the date of grant. The date of grant was February 7, 2023.
- F5. These Stock Appreciation Rights (SARs) were granted on February 6, 2024. 1,095 SARs became exercisable on the first anniversary of the date of grant and the remaining 2,192 SARs are scheduled to become exercisable in two substantially equal annual installments on the second and third anniversaries of the date of grant.
- F6. These SARs were granted on February 7, 2023. 2,062 SARs became exercisable on the first and second anniversaries of the date of grant. The remaining 1,032 SARs are scheduled to become exercisable on the third anniversary of the date of grant.
- F7. These SARs were granted on February 3, 2022 and became fully exercisable on the third anniversary of the date of grant.
- F8. These SARs were granted on February 5, 2021 and became fully exercisable on the third anniversary of the date of grant.
- F9. These SARs were granted on February 4, 2020 and became fully exercisable on the third anniversary of the date of grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
